Renal transplant patients at high risk of acute rejection benefit from adequate exposure to mycophenolic acid

Transplantation

Volumn 89, Issue 5, 2010, Pages 595-599

  Van Gelder, Teun ^a   Tedesco Silva, Helio ^b   De Fijter, Johan W ^c   Budde, Klemens ^d   Kuypers, Dirk ^e   Arns, Wolfgang ^f   Paul Soulillou, Jean ^g   Kanellis, John ^h   Zelvys, Arunas ⁱ   Ekberg, Henrik ^j   Holzer, Herwig ^k   Rostaing, Lionel ^l   Mamelok, Richard D ^m  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b HOSPITAL DO RIM E HIPERTENSÃO   (Brazil)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e UNIVERSITY OF LEUVEN   (Belgium)

^f Merheim General Center   (Germany)

^g NANTES UNIVERSITY HOSPITAL   (France)

^h MONASH MEDICAL CENTRE   (Australia)

ⁱ VILNIUS UNIVERSITY   (Lithuania)

^j LUND UNIVERSITY   (Sweden)

^k MEDICAL UNIVERSITY OF GRAZ   (Austria)

^l CHU RANGUEIL   (France)

^m Mamelok Consulting   (United States)

more..

Author keywords

Graft rejection; Mycophenolate mofetil; Therapeutic drug monitoring; Transplantation

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN A; HLA ANTIGEN; MYCOPHENOLIC ACID; PANEL REACTIVE ANTIBODY; TACROLIMUS;

ACUTE GRAFT REJECTION; ADULT; AFRICAN AMERICAN; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DELAYED GRAFT FUNCTION; DOSE RESPONSE; DRUG BLOOD LEVEL; HIGH RISK PATIENT; HISTOINCOMPATIBILITY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; POST HOC ANALYSIS; PRIORITY JOURNAL; RETRANSPLANTATION; SURGICAL PATIENT;

ANTIBIOTICS, ANTINEOPLASTIC; CHILD; DRUG ADMINISTRATION SCHEDULE; GRAFT REJECTION; HUMANS; INCIDENCE; KIDNEY TRANSPLANTATION; MYCOPHENOLIC ACID; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS;

EID: 77949385812     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181ca7d84     Document Type: Article

References (12)

1. Halloran P, Mathew T, TomlanovichS, et al. Mycophenolate mofetil in renal allograft recipients: A pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. The International Mycophenolate Mofetil Renal Transplant Study Groups. Transplantation 1997; 63: 39.
2. Johnson C, Ahsan N, Gonwa T, et al. Randomized trial of tacrolimus (prograf) in combination with azathioprine or mycophenolate mofetil versus cyclosporine (neoral) with mycophenolate mofetil after cadaveric kidney transplantation. Transplantation 2000; 69: 834.
3. Shaw LM, Korecka M, Venkataramana R, et al. Mycophenolic acid pharmacodynamics and pharmacokinetics provide a basis for rational monitoring strategies. Am J Transplant 2003; 3: 534.
4. Van Hest RM, Mathot RA, Pescovitz MD,etal. Explaining variability in mycophenolic acid exposure to optimize mycophenolate mofetil dosing: A population pharmacokinetic meta-analysis of mycophenolic acid in renal transplant recipients. J Am Soc Nephrol 2006; 17: 871.
5. Hale MD, Nicholls AJ, Bullingham RE, et al. The pharmacokinetic- pharmacodynamic relationship for mycophenolate mofetil in renal transplantation. Clin Pharmacol Ther 1998; 64: 672.
6. Van Gelder T. Mycophenolate mofetil: How to further improve using an already successful drug? Am J Transplant 2005; 5: 199.
7. Bennett WM. Immunosuppression with mycophenolic acid: One size does not fit all. J Am Soc Nephrol 2003; 14: 2414.
8. Le Meur Y, Büchler M, Thierry A, et al. Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation. Am J Transplant 2007; 7: 2496.
9. van Gelder T, Silva HT, de Fijter JW, et al. Comparing mycophenolate mofetil regimens for de novo renal transplant recipients: The fixed-dose concentration-controlled trial. Transplantation 2008; 86: 1043.
10. Kiberd BA, Lawen J,Fraser AD,etal. Early adequate mycophenolic acid exposure is associated with less rejection in kidney transplantation. Am J Transplant 2004; 4: 1079.
11. van Gelder T, Le Meur Y, Shaw LM, et al. Therapeutic drug monitoring of mycophenolate mofetil in transplantation. Ther Drug Monit 2006; 28: 145.
12. van Gelder T, Shaw LM. The rationale for and limitations of therapeutic drug monitoring for mycophenolate mofetil in transplantation. Transplantation 2005; 80: S244.